Kaito, Satoshi
Aoyama, Kazumasa
Oshima, Motohiko
Tsuchiya, Akiho
Miyota, Makiko
Yamashita, Masayuki
Koide, Shuhei
Nakajima-Takagi, Yaeko
Kozuka-Hata, Hiroko
Oyama, Masaaki http://orcid.org/0000-0001-6478-3735
Yogo, Takao http://orcid.org/0000-0003-4738-5668
Yabushita, Tomohiro
Ito, Ryoji http://orcid.org/0000-0003-2903-2332
Ueno, Masaya http://orcid.org/0000-0001-9177-8640
Hirao, Atsushi http://orcid.org/0000-0001-7818-8240
Tohyama, Kaoru
Li, Chao
Kawabata, Kimihito Cojin
Yamaguchi, Kiyoshi
Furukawa, Yoichi
Kosako, Hidetaka http://orcid.org/0000-0003-3228-6368
Yoshimi, Akihide http://orcid.org/0000-0002-0664-7281
Goyama, Susumu http://orcid.org/0000-0002-9339-1826
Nannya, Yasuhito
Ogawa, Seishi
Agger, Karl
Helin, Kristian http://orcid.org/0000-0003-1975-6097
Yamazaki, Satoshi
Koseki, Haruhiko http://orcid.org/0000-0001-8424-5854
Doki, Noriko http://orcid.org/0000-0002-8661-3179
Harada, Yuka
Harada, Hironori http://orcid.org/0000-0001-9401-5470
Nishiyama, Atsuya http://orcid.org/0000-0002-8416-3776
Nakanishi, Makoto http://orcid.org/0000-0002-6707-3584
Iwama, Atsushi http://orcid.org/0000-0001-9410-8992
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (19H05653, 19H05746)
Japan Agency for Medical Research and Development (21zf0127003h0001)
Article History
Received: 27 July 2023
Accepted: 2 July 2024
First Online: 28 August 2024
Competing interests
: K.H. is a co-founder of Dania Therapeutics, a consultant for Inthera Bioscience AG, and a scientific advisor for MetaboMed Inc. and Hannibal Innovation. All other authors declare no competing interests.